Please login to the form below
Novo-Nordisk
This page shows the latest Novo-Nordisk news and features for those working in and with pharma, biotech and healthcare.
Lilly’s Trulicity scores CV reduction indication in the US
The new MACE approval could help Lilly in its fight for market share with other GLP-1 agonists, including Novo Nordisk’s once-weekly drug Ozempic (semaglutide). ... Novo also has Rybelsus – oral semaglutide – in its arsenal, and analysts at Pareto
Latest news
-
New drugs drive Novo Nordisk despite insulin price pressures
Novo Nordisk has revealed its fourth quarter report, posting a surprise increase in sales for the quarter but forecasted pricing pressure on its insulin products could hurt overall growth this year. . ... Operations and Region Europe,” said Novo’s
-
Givlaari, Rybelsus lead crowded CHMP recommendations
Joining Givlaari with a positive recommendation was Rybelsus (semaglutide), Novo Nordisk’s once-daily oral formulation of its injectable GLP-1 agonist semaglutide. ... In Novo’s Pioneer programme of the drug, people treated with Rybelsus achieved
-
Havas Lynx Group and VCCP Health win big at PM Society Awards
Other pharma Gold winners included ALK, Heart UK, Immunocore, Janssen, Mundipharma, Novo Nordisk and Santen. ... Target Award for Advertisement Campaign: Havas Lynx Group for Novo Nordisk.
-
Lilly will aim for one $1bn-$5bn deal per quarter in 2020
As a result of the increasing criticism, Lilly, as well as other insulin manufacturers Sanofi and Novo Nordisk, have been making cheaper products available in response.
-
Novo Nordisk gets MACE prevention claim for Ozempic in US
We strongly believe in the benefits of semaglutide and this approval marks an important milestone,” commented Novo Nordisk’s chief science officer Mads Krogsgaard Thomsen. ... up data in Novo Nordisk’s fourth-quarter results statement, due on 5
More from news
Approximately 144 fully matching, plus 282 partially matching documents found.
Latest Intelligence
-
Novo Nordisk awakens its ‘Sleeping Beauty’
Novo Nordisk’s Biopharm is showing solid growth after a stuttering start, and its new leader believes a ‘sleeping beauty’ has been awoken. ... The small revolution we are also running in Novo Nordisk is to realise that we have many platforms at our
-
Darwinian leadership in the life sciences industry
I interviewed 23 CEOs and other executives from companies as varied as Novo Nordisk and Novartis to Smith &Nephew and B.Braun. ... And as Novo Nordisk’s Lars Fruergaard Jørgensen eloquently put it, at the overlap of health, science and business, there
-
Pharma industry consensus: fix data strategy before pushing artificial intelligence and machine learning applications
The old way of working will just not help.”. Thomas Thestrup-Terp, Vice President, Commercial Operations, Novo Nordisk, agrees unequivocally that organisations lack the good clean commercial data they need before
-
The fight for affordable insulin
The world’s three biggest insulin manufacturers are Novo Nordisk, Sanofi and Eli Lilly. ... Elizabeth takes issues with many of Lilly’s access claims (and those of Sanofi and Novo Nordisk), which don’t tally with the experience of her
-
Re-imagining content supply chains for a next-gen customer experience in pharma
According to Thomas Thestrup-Terp, Vice President, Commercial Operations at Novo Nordisk: “Novo Nordisk and many others are looking into the opportunity of decoupling creative generation of content from production. ... of producing fantastic marketing
More from intelligence
Approximately 6 fully matching, plus 37 partially matching documents found.
Latest appointments
-
New hires at Nanoform, Leo Pharma and Calliditas
He has previously worked in various positions at Novo Nordisk, most recently as its Senior Global Regulatory Lead. ... During his time at Novo Nordisk, he led the strategic regulatory input for the orphan drug NovoEight from phase 1 through phase 3.
-
Ashfield, Health Unlimited and Ashley Communications add to their teams
The latest med comms movers. Ashfield appoints Novo’s sales and marketing director. ... Van Weperen was most recently at diabetes giant Novo Nordisk, where he worked on delivering insulin and GLP1 biosimilar defence strategies, leading Novo’s UK
-
Healthcare Comms appointments
Thomas has previously held senior positions at Novo Nordisk including head of sales North, UK.
-
Lars Rebien Sørensen becomes chairman of Novo Holdings
He will take up the new role 1 July. Former Novo Nordisk CEO Lars Rebien Sørensen has been appointed as Novo Holdings’ new chairman. ... years. Sørensen will succeed Sten Scheibye - who retires effective 1 July - and he will also become chairman of
-
Novo Nordisk appoints new general manager
He said: “I am delighted to join Novo Nordisk in the role of general manager in the UK. ... The vision, values and passion that is immediately evident within the company makes Novo Nordisk and exciting organisation to be a part of.
More from appointments
Approximately 10 fully matching, plus 36 partially matching documents found.
Latest from PMHub
-
Addressing Climate Impact: The Healthcare Paradox
For the healthcare and pharmaceutical industry, the impact of climate change is twofold – responding to the increased risk of certain diseases and conditions and decarbonising their own processes and products to prevent worsening impact. Andrew
-
Terrence Higgins Trust appoints creative agency 11 London for new awareness campaign
Clients include Novo Nordisk, Teva, the World Health Organization, Breast Cancer Now and the UK Sepsis Trust – as well as RSPCA and the Campaign to Protect Rural England.
-
After a busy first quarter, emotive welcomes five new team members
She also holds a level 5 CIPD in HR management achieved during her time at Novo Nordisk. .
-
Innovative pricing and contracting options
Novo Nordisk, for instance, has partnered with certain cities to curb diabetes. ... Without pushing for their products, Novo Nordisk can succeed at promoting their participation in improving global care, which can also build trust with payers and
-
MIT reveals new pill to deliver insulin
A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. ... It’s my thesis project and I helped coordinate the efforts between MIT and Novo Nordisk.
More from PMHub
Approximately 2 fully matching, plus 48 partially matching documents found.
Featured jobs
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
- Digital Associate Director - Medcomms
-
£65000 - £80000 per annum
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Account Manager (PR)
-
Great Benefits
- Group Director of Medical Affairs and Scientific Strategy, Medic...
-
Substantial six figure package
-
Senior External Communications Lead
-
£Competitive Salary
-
Publications director
-
Competitive salary and bonus scheme
-
Account Manager
-
£Competitive Salary
-
Account Director, Medical Education
-
Salary TBC
-
Account director
-
Competitive salary and bonus scheme
-
Account Director
-
£Competitive Salary
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Account Director, Healthcare Communications
-
Salary TBC
-
Experienced medical editor
-
Competitive salary and bonus scheme
Subscribe to our email news alerts
- Immutep spikes on trial of its LAG-3 drug with Keytruda
- US backs Sanofi’s ‘fast-track’ coronavirus vaccine
- Coronavirus outbreak escalation could impact drug supply chain
- Researchers discover new antibiotic using AI
- Genital herpes vaccine candidate heads for human studies
- Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA
- AVENIR GLOBAL appoints global healthcare lead
- Bedrock Group bolsters team with three key appointments
- AXON recognised for ‘excellence in wellbeing’ by Great Place to Work
- Celgene’s Revlimid scores NICE approval in follicular lymphoma
- Lilly’s Cyramza narrowly clears FDA adcomm vote for first-line NSCLC
- Menlo slumps as itching drug fails mid-stage trial
PMHub
Create Health
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...
Latest intelligence
- The ALS patient journey
- Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
- Equipping your medical affairs teams with solutions to navigate the healthcare landscape
- Dr Tyler Ray, OPEN Health Medical Communications...
- Can protein degraders unlock ‘undruggable’ drug targets?
- Exploring a new and exciting area of small-molecule drug discovery...
Quick links
Infographics
